Instrument Inactif

Autres langues Aravive, Inc.

Actions

ARAV

US03890D1081

Recherche biotechnologique et médicale

Autres langues

31/01/24	Aravive, Inc.(NasdaqGS:ARAV) dropped from S&P TMI Index
26/01/24	Aravive, Inc.(NasdaqGS:ARAV) dropped from NASDAQ Composite Index
19/01/24	Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data
17/01/24	Aravive Shares Sink 53% After Hours on Plans to Voluntarily Terminate Listing on Nasdaq Global Select Market
17/01/24	Aravive, Inc. Announces Termination of Rudy C. Howard as Chief Financial Officer
17/01/24	Aravive, Inc. Announces Termination of Gail McIntrye as Chief Executive Officer
17/01/24	Aravive, Inc. Announces Board and Committee Resignations
17/01/24	Aravive, Inc. to Delist from The Nasdaq Stock Market
09/11/23	Aravive, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
19/10/23	The Street Reports: Guide to Penny Stocks Look Now! CLNV, ARAV, RDHL, ATHX, EPAZ
21/08/23	Aravive, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
03/08/23	Top Midday Decliners
02/08/23	Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
02/08/23	Aravive, Inc. Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
28/07/23	Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023
14/07/23	Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023
23/06/23	Aravive, Inc.(NasdaqGS:ARAV) added to Russell 3000E Growth Index
23/06/23	Aravive, Inc.(NasdaqGS:ARAV) added to Russell Microcap Growth Index
20/06/23	Virpax Pharmaceuticals Names New CFO
13/06/23	Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)
05/06/23	ARAVIVE, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
05/06/23	Aravive To Participate in the Jefferies Global Healthcare Conference
25/05/23	ARAVIVE, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
25/05/23	Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023
16/05/23	Aravive, Inc. Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma